Delcath Systems Inc. Common Stock. Replay the stock market charts of DCTH day by day back to 2003. Open long and short positions without spending any money. Delcath Systems, Inc. operates as a specialty pharmaceutical and medical device company focusing on cancers of the liver. The company is developing its proprietary product-Melphalan Hydrochloride for injection for use with the Delcath Hepatic Delivery System; and markets melphalan hydrochloride as a device under the trade name Delcath Hepatic CHEMOSAT Delivery System for Melphalan in Europe. Its primary focus is on the execution of its clinical development program in ocular melanoma liver metastases, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and certain other cancers that are metastatic to the liver. Delcath Systems, Inc. was founded in 1988 and is headquartered in New York, New York.
